Draft Guidance Addresses Company Requests For Rationale Of FDA Decisions
This article was originally published in The Gray Sheet
Executive Summary
The document offers FDA’s interpretation of the terms “substantive summary” and “significant decisions,” both of which appear in new statutory provisions related to the longstanding process for manufacturers to appeal an agency decision.